Two RNA sequencing inflammatory scores as predictors of benefit From pembrolizumab in advanced breast cancer

From Cancer Therapy Advisor by Susan Moench, PhD, PA-C

Prospective assessments of 2 RNA sequencing inflammatory signature scores, an 18-gene T-cell–inflamed gene expression profile (GEP), as well as a 37-gene tissue-resident memory (TRM) T-cell signature, both measured at baseline, as predictors of response to the programmed cell death 1 (PD-1) inhibitor, pembrolizumab, for patients with metastatic triple-negative breast cancer enrolled in the KEYNOTE-086 trial (ClinicalTrials.gov Identifier: NCT02447003) showed associations between both assays and clinical outcomes. The findings from this study were reported at the American Association for Cancer Research (AACR) Annual Meeting 2019.

(read more…)